论文部分内容阅读
目的研究Sox-10在神经鞘瘤和纤维型脑膜瘤中的表达情况及其鉴别诊断价值。方法应用免疫组化EnVision法检测Sox-10在50例肿瘤(30例神经鞘瘤和20例纤维型脑膜瘤)中的表达情况,并与S-100蛋白的表达行对比分析。结果 30例神经鞘瘤中29例(97%)Sox-10(+),阳性定位于细胞核;20例纤维型脑膜瘤中Sox-10均为(-)(100%)。30例神经鞘瘤中22例(73%)S-100(+),阳性定位于细胞核、细胞质和突起;20例纤维型脑膜瘤中15例(75%)S-100(+),定位于细胞核、细胞质和突起。Sox-10诊断神经鞘瘤的敏感度为97%,特异度为100%;S-100的敏感度为73%,特异度为25%。结论鉴别诊断神经鞘瘤与纤维型脑膜瘤,Sox-10是一种敏感度和特异度都优于S-100的免疫组化标记物。
Objective To study the expression of Sox-10 in schwannoma and fibro-meningioma and its differential diagnostic value. Methods The expression of Sox-10 in 50 tumors (30 schwannomas and 20 meningiomas) was detected by immunohistochemistry EnVision method and compared with that of S-100 protein. Results Sox-10 (+) was positive in 29 (97%) of the schwannomas and was localized in the nucleus. Sox-10 was found to be (-) (100%) in all 20 meningiomas. S-100 (+) was localized in the nucleus, cytoplasm and protrusions in 22 (73%) schwannomas and 15 (75%) S-100 (+) in 20 fibro- Nucleus, cytoplasm and protrusions. Sox-10 had a sensitivity of 97% and a specificity of 100% for diagnosis of schwannoma; S-100 had a sensitivity of 73% and a specificity of 25%. Conclusions Differential diagnosis of schwannoma and fibro-meningiomas is an immunohistochemical marker that is superior to S-100 in sensitivity and specificity.